Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease
Scientific Reports · 16.10.2024 · 14 (1)
DOI: 10.1038/s41598-024-74716-7 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Scientific Reports, online erschienen am 16.10.2024. Verfasst von Samuel Lessard und 27 weiteren Autor:innen. Beteiligte Einrichtung: Rare Blood Disorders, Sanofi, Waltham, MA, 02451, USA. samuel.lessard@sanofi.com. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fetal Hemoglobin, Gene Editing, Hematopoietic Stem Cells. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Biogen, Sangamo Therapeutics.
Abstract (Originalsprache)
BIVV003 is a gene-edited autologous cell therapy in clinical development for the potential treatment of sickle cell disease (SCD). Hematopoietic stem cells (HSC) are genetically modified with mRNA encoding zinc finger nucleases (ZFN) that target and disrupt a specific regulatory GATAA motif in the BCL11A erythroid enhancer to reactivate fetal hemoglobin (HbF). We characterized ZFN-edited HSC from healthy donors and donors with SCD. Results of preclinical studies show that ZFN-mediated editing is highly efficient, with enriched biallelic editing and high frequency of on-target indels, producing HSC capable of long-term multilineage engraftment in vivo, and express HbF in erythroid progeny. Interim results from the Phase 1/2 PRECIZN-1 study demonstrated that BIVV003 was well-tolerated in seven participants with SCD, of whom five of the six with more than 3 months of follow-up displayed increased total hemoglobin and HbF, and no severe vaso-occlusive crises. Our data suggest BIVV003 represents a compelling and novel cell therapy for the potential treatment of SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rare Blood Disorders, Sanofi, Waltham, MA, 02451, USA. samuel.lessard@sanofi.com.
- Precision Medicine and Computational Biology, Sanofi, Cambridge, MA, 02141, USA. samuel.lessard@sanofi.com.
- Rare Blood Disorders, Sanofi, Waltham, MA, 02451, USA.
- Sangamo Therapeutics, Richmond, CA, 94804, USA.
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institutes/National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, National Institutes of Health (NIH), Bethesda, MD,…
- Henry Ford Cancer Institute, Detroit, MI, USA.
Förderung
- Sanofi
- Biogen
- Sangamo Therapeutics
Zitieren
APA
Lessard, S., Rimmelé, P., Ling, H., Moran, K., Vieira, B., Lin, Y. D., Rajani, G. M., Hong, V., Reik, A., Boismenu, R., Hsu, B., Chen, M., Cockroft, B. M., Uchida, N., Tisdale, J., Alavi, A., Krishnamurti, L., Abedi, M., Galeon, I., …, & Hicks, A. (2024). Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-74716-7
Vancouver
Lessard S, Rimmelé P, Ling H, Moran K, Vieira B, Lin YD, et al. Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease. Scientific Reports. 2024;14(1). doi:10.1038/s41598-024-74716-7
BibTeX
@article{Lessard2024,
author = {Lessard, Samuel and Rimmelé, Pauline and Ling, Hui and Moran, Kevin and Vieira, Benjamin and Lin, Yi-Dong and Rajani, Gaurav Manohar and Hong, Vu and Reik, Andreas and Boismenu, Richard and Hsu, Ben and Chen, Michael and Cockroft, Bettina M and Uchida, Naoya and Tisdale, John and Alavi, Asif and Krishnamurti, Lakshmanan and Abedi, Mehrdad and Galeon, Isobelle and Reiner, David and Wang, Lin and Ramezi, Anne and Rendo, Pablo and Walters, Mark C and Levasseur, Dana and Peters, Robert and Harris, Timothy and Hicks, Alexandra},
title = {Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease},
journal = {Scientific Reports},
year = {2024},
volume = {14},
number = {1},
doi = {10.1038/s41598-024-74716-7}
}
EUVIMED